Chiesi Farmaceutici S.p.a.

Chiesi Farmaceuticals S.p.a.

Roberta Razzetti

Paolo Chiesi

Stefano Bongrani

Maurizio Civelli

Alberto Umile

Vittorino Servadio

Patrizio Vitulo

Massimo Giossi

Federico Bianco

Alessandro Bertani

The present invention concerns a method of treating an advanced lung disease in a patient in need thereof by lung transplantation.

Use of pulmonary surfactants in lung transplantation and methods thereof

Administration of a modified natural surfactant in combination with a corticosteroid is effective for the prevention of bronchopulmonary dysplasia (BPD) and lowers the markers of pulmonary oxidative stress.

Therapeutic combination comprising a pulmonary surfactant and a steroid

The use of racemic or optically active compounds represented by formula (I) and the salts thereof wherein R is H or CHfor the preparation of pharmaceutical compositions for the therapy of ophthalmic disorders.

2-Aminotetralin derivatives for the therapy of glaucoma

The invention relates to a method of treatment of left ventricular dysfunction, by administering to a subject suffering from left ventricular remodeling a therapeutically effective amount of 5,6-dihydroxy-2-methylaminotetralin or 5,6-diisobutyroyl-oxy-2-methyl-aminotetralin, or a pharmaceutically acceptable salt thereof.

Aminotetralin derivatives for the therapy of cardiovascular diseases

Left ventricular dysfunction is treated by a process, comprising: administering to a subject suffering from left ventricular remodeling a therapeutically effective amount of 5,6-dihydroxy-2-methylaminotetralin, or 5,6-diisobutyroyl-oxy-2-methyl-aminotetralin, or a pharmaceutically acceptable salt thereof in combination with an angiotensin-converting enzyme inhibitor.

Growing community of inventors

Parma, Italy

Roberta Razzetti